top of page

PDCO monthly report of opinions on paediatric investigation plans and other activities

The Paediatric Committee (PDCO) adopted opinions agreeing paediatric investigation plans (PIPs). A PIP sets out a programme for the development of a medicine in the paediatric population. The PIP aims to generate the necessary quality, safety and efficacy data through studies to support the authorisation of the medicine for use in children of all ages. These data have to be submitted to the European Medicines Agency, or national competent authorities, as part of an application for a marketing authorisation for a new medicine, or for one covered by a patent. In some cases, a PIP may include a waiver of the studies in one or more paediatric subsets, or a deferral.

Click on this link for more information.

#RegulatoryAffairsHuman #LegislationRegulatoryAffairs

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page